Proactiveinvestors United Kingdom Novartis AG (ADR) https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Novartis AG (ADR) RSS feed en Thu, 23 Jan 2020 08:43:18 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product https://www.proactiveinvestors.co.uk/companies/news/199971/adamis-pharmaceuticals-shares-skyrocket-on-news-of-novartis-distribution-deal-for-anaphylaxis-product-199971.html Mon, 02 Jul 2018 14:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199971/adamis-pharmaceuticals-shares-skyrocket-on-news-of-novartis-distribution-deal-for-anaphylaxis-product-199971.html Novartis pays 88% premium to gain control of AveXis https://www.proactiveinvestors.co.uk/companies/news/194489/novartis-pays-88-premium-to-gain-control-of-avexis-194489.html Mon, 09 Apr 2018 07:07:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194489/novartis-pays-88-premium-to-gain-control-of-avexis-194489.html Cerulean Pharma shares soar after news of Novartis tie-up https://www.proactiveinvestors.co.uk/companies/news/167655/cerulean-pharma-shares-soar-after-news-of-novartis-tie-up-167655.html Wed, 19 Oct 2016 15:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/167655/cerulean-pharma-shares-soar-after-news-of-novartis-tie-up-167655.html Novartis cuts guidance after cancer drug sales flop https://www.proactiveinvestors.co.uk/companies/news/128363/novartis-cuts-guidance-after-cancer-drug-sales-flop-128363.html Tue, 19 Jul 2016 14:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/128363/novartis-cuts-guidance-after-cancer-drug-sales-flop-128363.html Novartis’s eye care unit drives quarterly profit drop https://www.proactiveinvestors.co.uk/companies/news/121823/novartiss-eye-care-unit-drives-quarterly-profit-drop-121823.html Wed, 27 Jan 2016 12:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/121823/novartiss-eye-care-unit-drives-quarterly-profit-drop-121823.html Novartis' breakthrough Entresto receives FDA approval ahead of schedule https://www.proactiveinvestors.co.uk/companies/news/115209/novartis-breakthrough-entresto-receives-fda-approval-ahead-of-schedule-115209.html Wed, 08 Jul 2015 18:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/115209/novartis-breakthrough-entresto-receives-fda-approval-ahead-of-schedule-115209.html Novartis to buy privately held Spinifex for $200 mln https://www.proactiveinvestors.co.uk/companies/news/115208/novartis-to-buy-privately-held-spinifex-for-200-mln-115208.html Mon, 29 Jun 2015 16:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/115208/novartis-to-buy-privately-held-spinifex-for-200-mln-115208.html Novartis plans $5 bln share buyback; to add business segments https://www.proactiveinvestors.co.uk/companies/news/98643/novartis-plans-5-bln-share-buyback-to-add-business-segments-50103.html Fri, 22 Nov 2013 13:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/98643/novartis-plans-5-bln-share-buyback-to-add-business-segments-50103.html Novartis Q1 profit retreats 18% https://www.proactiveinvestors.co.uk/companies/news/85598/novartis-q1-profit-retreats-18-28136.html Tue, 24 Apr 2012 13:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/85598/novartis-q1-profit-retreats-18-28136.html Novartis to axe nearly 2,000 jobs in restructuring plan https://www.proactiveinvestors.co.uk/companies/news/82770/novartis-to-axe-nearly-2000-jobs-in-restructuring-plan-23444.html Fri, 13 Jan 2012 13:12:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/82770/novartis-to-axe-nearly-2000-jobs-in-restructuring-plan-23444.html Novartis' anti-osteoporosis drug fails to meet phase 3 study goals https://www.proactiveinvestors.co.uk/companies/news/81417/novartis-anti-osteoporosis-drug-fails-to-meet-phase-3-study-goals-21044.html Mon, 14 Nov 2011 18:36:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/81417/novartis-anti-osteoporosis-drug-fails-to-meet-phase-3-study-goals-21044.html Novartis to cut 2,000 jobs despite 15% hike in Q3 earnings https://www.proactiveinvestors.co.uk/companies/news/80854/novartis-to-cut-2000-jobs-despite-15-hike-in-q3-earnings-20137.html Tue, 25 Oct 2011 18:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/80854/novartis-to-cut-2000-jobs-despite-15-hike-in-q3-earnings-20137.html Novartis receives Japanese approval for MS drug and CAPS drug https://www.proactiveinvestors.co.uk/companies/news/80121/novartis-receives-japanese-approval-for-ms-drug-and-caps-drug-18917.html Tue, 27 Sep 2011 15:48:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/80121/novartis-receives-japanese-approval-for-ms-drug-and-caps-drug-18917.html Novartis meets primary goal of phase 3 trial for benign kidney tumour drug https://www.proactiveinvestors.co.uk/companies/news/80052/novartis-meets-primary-goal-of-phase-3-trial-for-benign-kidney-tumour-drug-18790.html Fri, 23 Sep 2011 17:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/80052/novartis-meets-primary-goal-of-phase-3-trial-for-benign-kidney-tumour-drug-18790.html Novartis gets positive opinion from European authorities for blood pressure drug https://www.proactiveinvestors.co.uk/companies/news/80048/novartis-gets-positive-opinion-from-european-authorities-for-blood-pressure-drug-18786.html Fri, 23 Sep 2011 16:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/80048/novartis-gets-positive-opinion-from-european-authorities-for-blood-pressure-drug-18786.html Novartis' childhood arthritis drug study achieves primary goal https://www.proactiveinvestors.co.uk/companies/news/79885/novartis-childhood-arthritis-drug-study-achieves-primary-goal-18477.html Fri, 16 Sep 2011 18:38:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/79885/novartis-childhood-arthritis-drug-study-achieves-primary-goal-18477.html Novartis' Afinitor drug meets primary goal of phase 3 trial for TSC drug https://www.proactiveinvestors.co.uk/companies/news/78527/novartis-afinitor-drug-meets-primary-goal-of-phase-3-trial-for-tsc-drug-16143.html Fri, 08 Jul 2011 16:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/78527/novartis-afinitor-drug-meets-primary-goal-of-phase-3-trial-for-tsc-drug-16143.html Novartis meets primary goal of phase 3 study for breast cancer drug https://www.proactiveinvestors.co.uk/companies/news/78433/novartis-meets-primary-goal-of-phase-3-study-for-breast-cancer-drug-15997.html Tue, 05 Jul 2011 13:11:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/78433/novartis-meets-primary-goal-of-phase-3-study-for-breast-cancer-drug-15997.html Novartis' NVA237 improves lung function in pulmonary disease patients https://www.proactiveinvestors.co.uk/companies/news/78394/novartis-nva237-improves-lung-function-in-pulmonary-disease-patients-15910.html Thu, 30 Jun 2011 15:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/78394/novartis-nva237-improves-lung-function-in-pulmonary-disease-patients-15910.html Novartis' Votubia brain tumour drug recommended for EU approval https://www.proactiveinvestors.co.uk/companies/news/78285/novartis-votubia-brain-tumour-drug-recommended-for-eu-approval-15751.html Fri, 24 Jun 2011 16:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/78285/novartis-votubia-brain-tumour-drug-recommended-for-eu-approval-15751.html Novartis study shows ACZ885 drug effective in treatment of gout https://www.proactiveinvestors.co.uk/companies/news/77743/novartis-study-shows-acz885-drug-effective-in-treatment-of-gout-14884.html Wed, 25 May 2011 16:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/77743/novartis-study-shows-acz885-drug-effective-in-treatment-of-gout-14884.html Novartis to buy cancer diagnostic specialist Genoptix in $330m deal https://www.proactiveinvestors.co.uk/companies/news/75885/novartis-to-buy-cancer-diagnostic-specialist-genoptix-in-330m-deal-11695.html The acquisition is expected to bolster Novartis' diagnostic unit, especially in oncology, and advance the company's ability to monitor individualized treatment programs.

]]>
Mon, 24 Jan 2011 18:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/75885/novartis-to-buy-cancer-diagnostic-specialist-genoptix-in-330m-deal-11695.html
Novartis' oral MS treatment receives recommendation for approval by EMA https://www.proactiveinvestors.co.uk/companies/news/75868/-novartis-oral-ms-treatment-receives-recommendation-for-approval-by-ema-11665.html Fri, 21 Jan 2011 19:40:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/75868/-novartis-oral-ms-treatment-receives-recommendation-for-approval-by-ema-11665.html Novartis' phase III study for meningitis vaccine meets primary endpoints https://www.proactiveinvestors.co.uk/companies/news/74462/novartis-phase-iii-study-for-meningitis-vaccine-meets-primary-endpoints--9471.html Mon, 25 Oct 2010 21:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/74462/novartis-phase-iii-study-for-meningitis-vaccine-meets-primary-endpoints--9471.html Trimeris amends two existing agreements for Fuzeon drug with both Roche and Novartis https://www.proactiveinvestors.co.uk/companies/news/73980/trimeris-amends-two-existing-agreements-for-fuzeon-drug-with-both-roche-and-novartis-8706.html Mon, 27 Sep 2010 18:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/73980/trimeris-amends-two-existing-agreements-for-fuzeon-drug-with-both-roche-and-novartis-8706.html Novartis receives EMA's recommendation for its Aflunov vaccine to protect against avian flu https://www.proactiveinvestors.co.uk/companies/news/73967/-novartis-receives-emas-recommendation-for-its-aflunov-vaccine-to-protect-against-avian-flu-8686.html Fri, 24 Sep 2010 23:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/73967/-novartis-receives-emas-recommendation-for-its-aflunov-vaccine-to-protect-against-avian-flu-8686.html Quark Pharmaceuticals enters licensing option agreement with Novartis for p53 suppression drug https://www.proactiveinvestors.co.uk/companies/news/73833/quark-pharmaceuticals-enters-licensing-option-agreement-with-novartis-for-p53-suppression-drug-7729.html Wed, 18 Aug 2010 19:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/73833/quark-pharmaceuticals-enters-licensing-option-agreement-with-novartis-for-p53-suppression-drug-7729.html